PHILADELPHIA – Surgeons at Penn Medicine are using a fluorescent dye that makes cancerous cells glow in hopes of identifying suspicious lymph nodes during head and neck cancer procedures. Led by Jason G. Newman, MD, FACS
, an associate professor of Otorhinolaryngology in the Perelman School of Medicine at the University of Pennsylvania, the study is the first in the world to look at the effectiveness of intraoperative molecular imaging (IMI) of lymph nodes in patients with head and neck cancer. Because the tumors glow, surgeons get real-time guidance to help them take out as much cancer as possible and leave non-diseased tissue alone.
Head and neck cancers make up about four percent of all cancers in the United States, according to the National Cancer Institute. There are several different types affecting the mouth, throat, voice box, sinuses, and salivary glands. Roughly 75 percent of these cancers are caused by tobacco and alcohol use, but a growing number are associated with human papillomavirus (HPV). Overall, researchers estimated more than 65,000 Americans will be diagnosed with head and neck cancers in 2017. Treatment can include surgery, radiation, chemotherapy, or a combination.
When these cancers spread or come back, lymph nodes are one of the most commonly involved areas. Lymph nodes serve as filters for the immune system, and many head and neck cancers spread there early in their course. Cancer in these lymph nodes can go undetected during surgery, meaning the procedure might leave microscopic cancerous cells inside a patient’s body. To minimize that risk, doctors often remove potentially suspicious lymph nodes during surgery, but that removal comes with the risk of damage to healthy tissue.
“By using a dye that makes cancerous cells glow, we get real time information about which lymph nodes are potentially dangerous and which ones we can leave alone,” Newman said. “That not only helps us remove more cancer from our patients during surgery, it also improves our ability to spare healthy tissue.”
It’s a concept already in practice for other disease sites in the Abramson Cancer Center’s Center for Precision Surgery, led by Sunil Singhal, MD, the William Maul Measey Associate Professor in Surgical Research. Singhal’s team has adopted the approach in lung cancer and brain cancer, and now Newman and his team are the first to specifically use IMI to look at lymph nodes. They’re using a contrast agent known as indocyanine green (ICG) – a fluorescent dye that was approved decades ago by the U.S. Food and Drug Administration for use in tracking blood flow.
“We know that tumors hold onto this dye longer than most other tissues, so if it is administered to a patient several hours before surgery, the tumors will still glow long after it has disappeared from the rest of the body,” Newman said.
Newman says this trial will set the stage for the use of fluorescent dyes in head and neck cancer surgery and neck lymph nodes. This will provide guidance on whether ICG is the most accurate dye specifically for lymph nodes, or if another contrast agent may make more sense.
“As we build this program, we’ll learn which dyes work best for which cancers,” he said.
Newman says this study can also help doctors use imaging to understand patterns of lymph node metastasis, which could help oncologists and surgeons predict and anticipate which patients are at the highest risk of spread or recurrence.
The study is supported by the American Philosophical Society, the National Institutes of Health (1F32CA210409, R01 CA193556), and the Association for Academic Surgery Foundation.
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation’s first medical school) and the University of Pennsylvania Health System, which together form a $8.6 billion enterprise.
The Perelman School of Medicine has been ranked among the top medical schools in the United States for more than 20 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $494 million awarded in the 2019 fiscal year.
The University of Pennsylvania Health System’s patient care facilities include: the Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center—which are recognized as one of the nation’s top “Honor Roll” hospitals by U.S. News & World Report—Chester County Hospital; Lancaster General Health; Penn Medicine Princeton Health; and Pennsylvania Hospital, the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.
Penn Medicine is powered by a talented and dedicated workforce of more than 43,900 people. The organization also has alliances with top community health systems across both Southeastern Pennsylvania and Southern New Jersey, creating more options for patients no matter where they live.
Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2019, Penn Medicine provided more than $583 million to benefit our community.